Injection apparatus and method of use

ABSTRACT

The present disclosure relates to a system and kit for preparing a reconstitutable cytotoxic pharmaceutical formulation within a closed system to prevent unintended contact with or release of the cytotoxic pharmaceutical formulation. A safety connector and a vial adapter are provided, which include check valves that prevent the unintended release of the cytotoxic pharmaceutical formulation. Also disclosed herein are methods of using the system and kit.

CROSS REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of U.S. application Ser. No.17/704,911, filed Mar. 25, 2022, which is a continuation of PCTApplication No. PCT/US2021/064095, filed Dec. 17, 2021, which claimspriority to U.S. Application Ser. No. 63/126,660, filed Dec. 17, 2020,the entire contents of which are herein incorporated in the presentapplication by reference.

FIELD OF THE DISCLOSURE

The present invention relates generally to injection apparatus and kits,and method of use thereof, and more particularly to injection apparatusand methods for both preparing and administering a pharmaceutical agentto a subject.

BACKGROUND

Glaucoma is a disease resulting in loss of visual field and ultimatelyblindness. Its most common symptom is elevated intraocular pressure(IOP), which can be treated by lowering or controlling IOP throughprescription eye drops, oral medications, laser treatment, surgery or acombination of these. For glaucoma surgery, trabeculectomy withadjunctive mitomycin C (MMC) treatment is the gold standard when asignificant sustained reduction in IOP is needed. At the same time,finding the optimal technique and tools for application of MMC hasremained a challenge. Mitomycin-C is an alkylating, anti-tumorantimetabolite used in ophthalmic surgery for its ability to inhibitfibroblast proliferation and suppress vascular ingrowth. Due to itscytotoxic nature, the packaging, dosage, route of delivery, applicationtime and area of tissue exposure must all be controlled carefully tominimize the risk of complications following MMC administration.Possible serious complications include severe inflammation, endothelialcell damage, endothelial cell loss, and hypotony. A significant needremains for reliable, less-irritating, yet sterile delivery apparatusand methods for ophthalmological applications of MMC and other similarlycytotoxic pharmaceutical agents.

SUMMARY OF THE DISCLOSURE

Provided herein is a method of preparing a cytotoxic formulation foradministration to a tissue. The method includes providing a sterile,closed system that includes: a sealed container of a single dose of acytotoxic pharmaceutical agent in a reconstitutable form; a carriercontaining a sterile liquid; a safety connector comprising a checkvalve, the safety connector permanently connected to the carrier; a vialadapter comprising a check valve, a vial end, and a syringe end, thevial adapter operable to removably connect to the sealed container via aspike at the vial end and connect to the safety connector at the syringeend; and a sterile syringe operable to connect to the vial adapter. Themethod further includes connecting the safety connector to the syringeend of the vial adapter, thereby opening the check valve in the safetyconnector and the check valve in the vial adapter; pushing the vial endof the vial adapter onto the sealed container, thereby piercing a lid ofthe sealed container with the spike; injecting the entire sterile waterfrom the carrier into the vial, via the safety connector and the vialadapter; inverting the sealed container repeatedly to mix the cytotoxicpharmaceutical agent and sterile liquid to form a reconstitutedcytotoxic formulation; disconnecting the vial adapter from the safetyconnector; connecting the sterile syringe to the vial adapter; andwithdrawing a predetermined volume of the reconstituted cytotoxicformulation into the sterile syringe.

In some embodiments, the administration may be performed via injection.In some embodiments, the predetermined volume may be less than or equalto 1 mL. In some examples, the predetermined volume may be 0.1 mL. Insome embodiments, the reconstituted cytotoxic formulation may have aconcentration of about 0.01 mg/mL to about 1 mg/m L. In some examples,the reconstituted cytotoxic formulation may have a concentration of 0.2mg/m L. In some embodiments, the pharmaceutical agent may include atleast one antimetabolite agent. In some examples, the at least oneantimetabolite agent may include mitomycin-C.

In some embodiments, the method may further include disconnecting thesterile syringe from the vial adapter; attaching a needle to the sterilesyringe; and injecting the reconstituted cytotoxic formulation of theperiocular tissue of a patient.

Further provided herein is a method of treating glaucoma. The methodincludes providing a sterile, closed system that includes: a sealedcontainer of a single dose of a cytotoxic pharmaceutical agent in areconstitutable form; a carrier containing a sterile liquid; a safetyconnector comprising a check valve, the safety connector permanentlyconnected to the carrier; a vial adapter comprising a check valve, avial end, and a syringe end, the vial adapter operable to removablyconnect to the sealed container via a spike at the vial end and connectto the safety connector at the syringe end; and a sterile syringeoperable to connect to the vial adapter. The method further includesconnecting the safety connector to the syringe end of the vial adapter,thereby opening the check valve in the safety connector and the checkvalve in the vial adapter; pushing the vial end of the vial adapter ontothe sealed container, thereby piercing a lid of the sealed containerwith the spike; injecting the entire sterile water from the carrier intothe vial, via the safety connector and the vial adapter; inverting thesealed container repeatedly to mix the cytotoxic pharmaceutical agentand sterile liquid to form a reconstituted cytotoxic formulation;disconnecting the vial adapter from the safety connector; connecting thesterile syringe to the vial adapter; withdrawing a predetermined volumeof the reconstituted cytotoxic formulation into the sterile syringe;disconnecting the sterile syringe from the vial adapter; attaching aneedle or cannula to the sterile syringe; and injecting thereconstituted cytotoxic formulation to the periocular tissue of apatient in need thereof.

In some embodiments, the administration may be performed via injection.In some embodiments, the predetermined volume may be less than or equalto 1 mL. In some examples, the predetermined volume may be 0.1 mL. Insome embodiments, the reconstituted cytotoxic formulation may have aconcentration of about 0.01 mg/mL to about 1 mg/m L. In some examples,the reconstituted cytotoxic formulation may have a concentration of 0.2mg/m L. In some embodiments, the pharmaceutical agent may include atleast one antimetabolite agent. In some examples, the at least oneantimetabolite agent may include mitomycin-C.

Further provided herein is a method of treating glaucoma. The methodincludes preparing a reconstituted cytotoxic pharmaceutical formulationin a sterile, closed system; and administering a predetermined volume ofthe reconstituted cytotoxic pharmaceutical formulation to a patient inneed thereof. In some embodiments, the sterile, closed system mayinclude a sealed container of a single dose of a cytotoxicpharmaceutical agent in a reconstitutable form; a carrier containing asterile liquid and connected to a safety connector, the safety connectorcomprising a check valve, the safety connector permanently connected tothe carrier; a vial adapter comprising a check valve, a vial end, and asyringe end, the vial adapter operable to removably connect to thesealed container via a spike at the vial end and connect to the safetyconnector at the syringe end; and a sterile syringe operable to connectto the vial adapter.

In some embodiments, the administration may be performed via injection.In some embodiments, the predetermined volume may be less than or equalto 1 mL. In some examples, the predetermined volume may be 0.1 mL. Insome embodiments, the reconstituted cytotoxic formulation may have aconcentration of about 0.01 mg/mL to about 1 mg/m L. In some examples,the reconstituted cytotoxic formulation may have a concentration of 0.2mg/m L. In some embodiments, the pharmaceutical agent may include atleast one antimetabolite agent. In some examples, the at least oneantimetabolite agent may include mitomycin-C.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows an exemplary system of the present disclosure provided in akit.

FIG. 2 shows an exemplary safety connector of the present disclosure.

FIGS. 3A-3D show the safety connector connected to the carrier invarious configurations. FIG. 3A shows the safety connector connected tothe carrier prior to inserting the plunger rod. FIG. 3B shows the safetyconnector connected to the carrier after insertion of the plunger rood.FIG. 3C shows a view of the distal end of the safety connector. FIG. 3Dshows an isometric view of the safety connector.

FIGS. 4A-4C show an exemplary vial adapter of the present disclosure.FIG. 4A shows a side view of the vial adapter. FIG. 4B shows anisometric view of the vial adapter, including the spike. FIG. 4C showsan isometric view of the carrier end of the vial adapter.

FIG. 5A shows the safety connector connected to both the vial adapterand to the carrier. FIG. 5B shows a close-up view of the safetyconnector connected to the vial adapter.

FIGS. 6A-6C show the tray containing sterile, absorbent pads of thepresent disclosure. FIG. 6A shows an isometric view of the tray. FIG. 6Bshows the tray with the safety connector affixed to the firstcylindrical connector and the TB syringe connected to the secondcylindrical connector for closed system venting. FIG. 6C shows aside-view of the tray with the safety connector affixed to the firstcylindrical connector and the TB syringe connected to the secondcylindrical connector.

FIGS. 7A-7H show diagrams for using the system of the present disclosureto prepare sponges saturated with the reconstituted pharmaceuticalagent.

FIGS. 8A-8H show diagrams for using the system of the present disclosureto prepare a reconstituted pharmaceutical agent suitable for injection.

DETAILED DESCRIPTION

Before the present invention is disclosed and described, it is to beunderstood that this invention is not limited to the particular methods,compositions, or materials disclosed herein, but is extended toequivalents thereof as would be recognized by those ordinarily skilledin the relevant arts. It should also be understood that terminologyemployed herein is used for the purpose of describing particularembodiments only and is not intended to be limiting.

Concentrations, amounts, and other numerical data may be expressed orpresented herein in a range format. It is to be understood that such arange format is used merely for convenience and brevity and should beinterpreted flexibly to include not only the numerical values explicitlyrecited as the limits of the range, but also to include all theindividual numerical values or sub-ranges encompassed within that rangeas if each numerical value and sub-range is explicitly recited. As anillustration, a numerical range of “about 2 to about 50” should beinterpreted to include not only the explicitly recited values of 2 to50, but also include all individual values and sub-ranges within theindicated range. Thus, included in this numerical range are individualvalues such as 2, 2.4, 3, 3.7, 4, 5.5, 10, 10.1, 14, 15, 15.98, 20,20.13, 23, 25.06, 30, 35.1, 38.0, 40, 44, 44.6, 45, 48, and sub-rangessuch as from 1-3, from 2-4, from 5-10, from 5-20, from 5-25, from 5-30,from 5-35, from 5-40, from 5-50, from 2-10, from 2-20, from 2-30, from2-40, from 2-50, etc. This same principle applies to ranges recitingonly one numerical value as a minimum or a maximum. Furthermore, such aninterpretation should apply regardless of the breadth of the range orthe characteristics being described.

As used herein, the term “about” is used to provide flexibility to anumerical range endpoint by providing that a given value may be “alittle above” or “a little below” the endpoint. For example, theendpoint may be within 10%, 8%, 5%, 3%, 2%, or 1% of the listed value.Further, for the sake of convenience and brevity, a numerical range of“about 50 mg/mL to about 80 mg/m L” should also be understood to providesupport for the range of “50 mg/mL to 80 mg/m L.” The endpoint may alsobe based on the variability allowed by an appropriate regulatory body,such as the FDA, USP, etc.

In this disclosure, “comprises,” “comprising,” “containing,” and“having” and the like can have the meaning ascribed to them in U.S.Patent Law and can mean “includes,” “including,” and the like, and aregenerally interpreted to be open ended terms. The terms “consisting of”or “consists of” are closed terms, and include only the components,structures, steps, or the like specifically listed in conjunction withsuch terms, as well as that which is in accordance with U.S. Patent law.“Consisting essentially of” or “consists essentially of” have themeaning generally ascribed to them by U.S. Patent law. In particular,such terms are generally closed terms, with the exception of allowinginclusion of additional items, materials, components, steps, orelements, that do not materially affect the basic and novelcharacteristics or function of the item(s) used in connection therewith.For example, trace elements present in a composition, but not affectingthe composition's nature or characteristics would be permissible ifpresent under the “consisting essentially of” language, even though notexpressly recited in a list of items following such terminology. In thisspecification when using an open ended term, like “comprising” or“including,” it is understood that direct support should be affordedalso to “consisting essentially of” language as well as “consisting of”language as if stated explicitly and vice versa.

I. System

Provided herein is a system for reconstituting a cytotoxicpharmaceutical formulation. The system enables the safe and simplifiedpreparation of a pharmaceutical agent such as mitomycin-C for transientapplication of the pharmaceutical agent. The preparation of thepharmaceutical agent takes place in a closed system to avoid unintendedcontact with the pharmaceutical agent or release of the pharmaceuticalagent. Several of the component parts are known in the prior art in oneform or another. Therefore, these component parts are not described indetail.

Referring now to FIG. 1 , the system includes a sealed container 10 ofthe pharmaceutical agent, a syringe 12, a carrier 14, a safety connector60, a vial adapter 66, and a mixing tray 16. As stated earlier, each ofthese component parts can be constructed of the materials typically usedto manufacture similar parts.

The sealed container 10 has a construction that is known in the art. Insome embodiments, the sealed container may contain cytotoxic agents suchas antimetabolite agents. In some examples, the pharmaceutical agent mayinclude mitomycin-C. More details regarding the pharmaceutical agentswithin the scope of the present disclosure are provided in Section IVbelow. In some embodiments, the sealed container 10 may be apharmaceutical vial. The sealed container 10 has a top 24 that can bepierced by a spike provided on a vial adapter 66 of the presentdisclosure, which seals closed after the spike 72 is removed from thetop 24 of the sealed container.

The sterile syringe 12 also has the typical construction of a syringe.In a preferred embodiment of the invention, the syringe 12 is a one ccsyringe, such as a tuberculin syringe (also referred to herein as a “TBsyringe”). The sterile syringe 12 has a plunger 26 that is manuallywithdrawn from the body of the sterile syringe to produce a suctionforce at the distal tip 28 of the sterile syringe.

The carrier 14 also has the construction of any known carrier. In someembodiments, the carrier 14 may be a syringe. In embodiments where thecarrier is a syringe, the carrier may be referred to as a “firstsyringe” and the sterile syringe may be referred to as the “secondsyringe.” The carrier includes a sterile liquid. In a preferredembodiment, the sterile liquid is sterile water. In other embodiments,the sterile liquid is sterile saline. The amount of sterile liquid isprovided to mix with the pharmaceutical agent contained by the sealedcontainer 10 to reconstitute the pharmaceutical agent in the sealedcontainer 10. The carrier 14 has a proximal end 30 that includes asafety connector 60 of the present disclosure described in more detailbelow The carrier distal end 32 includes a rubber plunger 20 adapted toreceive a plunger rod 22 to push the sterile liquid out of the carrier14. In some embodiments, the plunger rod 22 may have a threaded end thatscrews into the rubber plunger 20. The carrier 14 and the plunger rod 22may be packaged disassembled.

The system includes a safety connector 60, shown in FIG. 2 . As shown inFIGS. 3A-3D, the safety connector 60 is connected to the distal end ofthe carrier 14. The safety connector 60 includes a carrier end 62connected to the carrier 14, a distal end 64 operable to connect to thevial adapter 66 and the first cylindrical connector 50 of the tray, anda check valve that opens only when the safety connector 60 is properlyconnected to the vial adapter 66 or to the first cylindrical connector50. When the safety connector is not connected to vial adapter 66 or thefirst cylindrical connector 50, the check valve remains in a closedposition; thus, there is no flow in or out of the carrier 14. Thisensures that the sterile liquid remains sterile during storage andprevents leaking both before and after reconstitution of thepharmaceutical agent. In some embodiments, the carrier end 62 of thesafety connector 60 may be permanently connected to the proximal end 30of the carrier 14. In other embodiments, the carrier end 62 of thesafety connector 60 may be removably connected to the proximal end 30 ofthe carrier 14.

The system includes a vial adapter, shown in FIGS. 4A-4C. The vialadapter 66 is operable to reversibly connect to the safety connector 60and to the sealed container 10. The vial adapter 66 includes a syringeend 68, a vial end 70, and a check valve that opens only when the vialadapter 66 is properly connected to the safety connector 60 and to thesealed container 10. The syringe end 68 of the vial adapter 66 may beoperable to connect to the safety connector 60 and to the sterilesyringe 12. The vial end 70 of the vial adapter 66 includes a spike 72that is operable to pierce a membrane of the sealed container. When thevial adapter 66 is properly connected to the safety connector 60 and tothe sealed container 10, as shown in FIGS. 5A-5B, the diluent in thecarrier may be pushed through the carrier 14 into the sealed container10 for reconstitution of the pharmaceutical agent. In some embodimentsafter reconstitution of the pharmaceutical agent, the pharmaceuticalagent may be drawn back through the vial adapter 66 and the safetyconnector 60 into the carrier 14. In other embodiments afterreconstitution of the pharmaceutical agent, the carrier 14 with thesafety connector 60 may be disconnected from the syringe end 68 of thevial adapter 66, the safety syringe 12 may be connected to the syringeend 68 of the vial adapter 66, and a volume of the reconstitutedpharmaceutical agent may be drawn into the sterile syringe 12.

The system includes a tray 16 shown in FIGS. 6A-6C. The tray iscomprised of a tray body 34 and a tray cover 36. Preferably thematerials of the body 34 and cover 36 are substantially clear, inertplastic materials that may be employed in containing a pharmaceuticalagent such as mitomycin-C.

The tray body 34 has a rectangular block configuration with opposite top38 and bottom exterior surfaces, and a plurality of side exteriorsurfaces. A pair of arms project outwardly from one of the tray sidesurfaces 42. The arms 44 have axially aligned post holes that functionas pivot connections for the cover 36. The cover 36 is operable to openand close.

A compartment 48 is recessed into the top surface 38 of the tray. Asshown in the drawing figures, the compartment 48 has a rectangularconfiguration and defines an interior compartment having an interiorvolume between the tray top 38 and bottom surfaces, and the tray sidesurfaces 42. The interior volume of the compartment 48 is accessiblethrough the top opening of the cavity in the tray top surface 38. Theinterior volume of the compartment 48 is properly sized to accommodatethe combined volume of sponges 58 and the quantity of diluent in thecarrier 14.

A pair of first 50 and second 52 cylindrical connectors projectoutwardly from opposite side surfaces of the tray 34. The firstconnector 50 has a first interior passage 54 that extends through theconnector 50 and through the tray 34. The first passage 54 communicatesthe exterior environment of the tray with the tray compartment 48. Thefirst cylindrical connector 50 is operable to removably connect to thesafety connector 60. When the safety connector 60 is connected to thefirst cylindrical connector 50, the first passage 54 is in communicationwith the carrier 14 and the safety connector 60. The second connector 52has a second interior passage 56 that extends through the connector andthe tray 34. The second passage 56 also communicates the exteriorenvironment of the tray 34 with the tray compartment 48. The secondcylindrical connector 52 is operable to reversibly connect to thesterile syringe 12. The first passage 54 and the second passage 56 areseparate from each other and are separate from the top opening of thecompartment 48.

The sterile syringe 12 is operable to connect to the second cylindricalconnector 52 of the tray 34 and/or to the syringe end 68 of the vialadapter 66. When connected to the second cylindrical connector 52, thesterile syringe 12 is operable to aspirate air and/or liquid from thetray compartment 48 by a suction force. When connected to the syringeend 68 of the vial adapter 66, the sterile syringe 12 is operable towithdraw a volume of the reconstituted pharmaceutical agent from thesealed container 10. The volume may be a predetermined volume selectedfrom 0.1 mL, 0.2 mL, 0.3 mL, 0.4 mL, 0.5 mL, 0.6 mL, 0.7 mL, 0.8 mL, 0.9mL, or 1 mL. In some embodiments, the full volume of the reconstitutedpharmaceutical agent in the vial may not be withdrawn into the sterilesyringe.

The tray compartment 48 has an interior volume that is dimensioned toreceive and accommodate one or more sterile absorbent pads or sponges 58in the compartment 48. In the preferred embodiment, the sterileabsorbent pads or sponges 58 are constructed of an absorbent materialthat is known in the art and is used for the transient application of apharmaceutical agent such as mitomycin-C. An example of such a pad is aWeck-Cel™™ type surgical sponge provided by Medtronic Xomed, Inc. Thesterile absorbent pads or sponges are pre-cut into multiple shapes andsizes so that the surgeon or other healthcare professional can selectthe appropriate pad or sponge for his or her patient. In a preferredembodiment, the sterile absorbent pads or sponges range from 1-10 mm,2-8 mm, and preferably 3 mm to 6 mm in size, and come in an array ofshapes such as rectangles, circles, squares, and half-moons. Providingthe array of pre-cut, sterile pads or sponges enables the medicalprofessional to keep the treatment area clean and to select the size orshape of pad or sponge most appropriate for the treatment area.Furthermore, because the sterile absorbent pads or sponges are pre-cut,this eliminates the incidence of sponge fragmentation, preventing safetyissues associated with this problem. Additionally, the volume of thefluid in the carrier 14 may be matched with the volume of the pads orsponges, which leads to a reliable and repeatable volume of drug beingdelivered to the operative site.

II. Kit

Further provided herein is a kit for preparing a cytotoxic formulationfor administration to a tissue. An exemplary kit of the presentdisclosure is shown in FIG. 1 . The components of the system of thepresent disclosure may be provided in a kit. The kit includes a sealedcontainer of a single dose of a cytotoxic pharmaceutical agent in areconstitutable form, a carrier containing a sterile liquid, a safetyconnector, a vial adapter, and a sterile packaging container. Thecarrier, safety connector, and the vial adapter are described in moredetail in Section I. The pharmaceutical agent in a reconstitutable formis described in more detail in Section IV. In some embodiments, the kitmay further include a tray, described in more detail in Section I. Insome additional embodiments, the kit may further include a sterilesyringe, described in more detail in Section I. In still furtherembodiments, the kit may further include a syringe plunger.

The sterile packaging container includes an internal volume. Theinternal volume is sealed such that the contents of the internal volumeand the environment of the internal volume remain sterile. The internalvolume houses the sealed container, the carrier connected to the safetyconnector, and the vial adapter. In some embodiments, the kit mayinclude an instruction slip for user direction. The instruction slip mayinclude diagrams, photographs, text, etc. to properly instruct a user onhow to safely use the system of the present disclosure.

In some embodiments, the kit may include a waste container. The wastecontainer may be suitable for disposal of medical waste, biohazardouswaste, and/or chemical waste. In some aspects, the waste container maybe a bag. In a preferred embodiment, the waste container is achemotherapy waste disposal bag.

In some embodiments, the kit may include a non-sterile outer packagingcontainer. The non-sterile outer packaging container may include a boxor a bin. In some embodiments, the non-sterile outer packaging containermay have a peel-away lid. The non-sterile outer packaging containerallows for non-sterile handling of the kit prior to the kit's use. Insome embodiments, the non-sterile outer packaging may have a sterileinternal volume.

In an embodiment, the kit may be used to prepare a sterile cytotoxicformulation for administration to a tissue using the absorbent pads orvia injection using the sterile syringe. The kit provides the benefitversatility to a surgeon, such that either method of administration isavailable from a single kit. In some embodiments, the selection of usingthe absorbent pads or the injection may depend on the specific patient,experience of the surgeon, or other varying conditions. Having a kitthat can be used in two separate ways reduces both manufacturing costsand cost to the user.

III. Method

Further provided herein is a method of preparing a cytotoxic formulationfor administration to a tissue. The method includes providing a sterile,closed system described in Section I. The method further includesconnecting the safety connector to the syringe end of the vial adapter,thereby opening the check valve in the safety connector and the checkvalve in the vial adapter; pushing the vial end of the vial adapter ontothe sealed container thereby piercing a lid of the sealed container withthe spike; injecting the entire sterile diluent from the carrier intothe vial via the safety connector and the vial adapter; inverting thesealed container repeatedly to mix the cytotoxic pharmaceutical agentand the sterile liquid to form a reconstituted cytotoxic formulation;withdrawing a volume of the cytotoxic formulation back into the carrier;and disconnecting the safety connector from the vial adapter, therebyclosing the check valve in the safety connector and closing the checkvalve in the vial adapter, wherein the safety connector remainsconnected to the carrier and the vial adapter remains connected to thesealed container. In some embodiments, the pharmaceutical agent may bemitomycin-C. The method may further include disposing of one or more ofthe components of the system after use in a waste container, and thensubsequently disposing of the waste container.

In some embodiments, the method may further include shaking the sealedcontainer after the inverting and before the withdrawing to ensure allof the pharmaceutical agent is reconstituted.

In some embodiments, the method may further include letting the sealedcontainer stand at room temperature after the inverting and before thewithdrawing to allow all of the product to dissolve.

In some embodiments, the concentration of the cytotoxic formulationwithdrawn into the carrier may be at least about 0.01 mg/mL. In someadditional embodiments, the concentration of the cytotoxic formulationwithdrawn into the carrier may be at least about 0.01 mg/mL to at leastabout 1 mg/mL. In some aspects, the concentration of the cytotoxicformulation withdrawn into the carrier may be at least about 0.01 mg/mL,0.02 mg/mL, 0.03 mg/mL, 0.04 mg/mL, 0.05 mg/mL, 0.06 mg/mL, 0.07 mg/mL,0.08 mg/mL, 0.09 mg/mL 0.1 mg/mL, 0.2 mg/mL, 0.3 mg/mL, 0.4 mg/mL, 0.5mg/mL, 0.6 mg/mL, 0.7 mg/mL, 0.8 mg/mL, 0.9 mg/mL, or at least about 1mg/mL. In a preferred embodiment wherein the pharmaceutical agent ismitomycin-C, the concentration of the cytotoxic formulation withdrawninto the carrier is at least about 0.1 mg/mL mitomycin-C.

In some embodiments, the method may further include connecting thesafety connector to a first cylindrical connector of a tray andconnecting a sterile syringe to a second cylindrical connector of thetray. The tray and the components of the tray are described in moredetail in Section I. The compartment of the tray may include at leastone sterile, absorbent pad. In some additional embodiments, the methodmay further include injecting the volume of the cytotoxic formulationinto the compartment of the tray, thereby saturating the at least onesterile, absorbent pad with the cytotoxic formulation, and withdrawingany excess cytotoxic formulation and/or air into the sterile syringe. Insome aspects, the cytotoxic formulation may remain undisturbed in thetray for at least 60 seconds before withdrawing any excess cytotoxicformulation and/or air into the sterile syringe. In further embodiments,one or more of the sterile, absorbent pads may be removed from thecompartment of the tray before connecting the safety connector and thesterile syringe to the first cylindrical connector and the secondcylindrical connector, respectively.

Further provided herein is a method of administering a cytotoxicformulation to a tissue. The method includes preparing a cytotoxicformulation as described above, removing one or more saturated sterile,absorbent pads from the compartment of the tray, and then applying theone or more saturated sterile, absorbent pads to the tissue. In someembodiments, the safety connector and the sterile syringe may remainconnected to the first cylindrical connector and the second cylindricalconnector, respectively, when the one or more saturated sterile,absorbent pads are removed from the compartment of the tray. In someadditional embodiments, the administration of the cytotoxic formulationoccurs within one hour after the reconstitution of the pharmaceuticalagent.

In some embodiments, the method further includes removing the one ormore saturated sterile, absorbent pads from the tissue after a period oftime. In some aspects, the period of time may be 30 seconds, 1 minute,1.5 minutes, 2 minutes, 2.5 minutes, 3 minutes, or longer than 3minutes. In a preferred embodiment, the period of time is 2 minutes.

In some embodiments the tissue may be periocular tissue. In someaspects, the periocular tissue may include an episcleral (sub-Tenon's)space. In embodiments when the tissue is periocular tissue, the methodmay further include performing a peritomy after removing the one or moresaturated sterile, absorbent pads. In some aspects, the perioculartissue may receive at least 0.1 mL of the cytotoxic formulation via theone or more sterile, absorbent pads.

When the one or more absorbent pads are removed from the tissue, theymay be returned to the tray compartment. The cover of the tray may thenbe moved to a closed position with the used absorbent pads inside. Thetray, absorbent pads, safety connector, sterile syringe, and carrier maythen be placed in the waste container for disposal. In some embodiments,safety connector and the sterile syringe are still connected to the traywhen placed in the waste container to prevent release of the cytotoxicformulation.

Further provided herein is a method of preparing a predetermined dose ofa pharmaceutical agent for administration to a patient. The methodincludes providing a system described in Section I, optionally in theform of a kit described in Section II, connecting the plunger rod to thecarrier (as shown in FIG. 8A); connecting the safety connector to thesyringe end of the vial adapter (as shown in FIG. 8B), thereby openingthe check valve in the safety connector and the check valve in the vialadapter; pushing the vial end of the vial adapter onto the sealedcontainer thereby piercing a lid of the sealed container with the spike(as shown in FIG. 8C); injecting the entire sterile diluent from thecarrier into the vial via the safety connector and the vial adapter (asshown in FIG. 8D); inverting the sealed container repeatedly to mix thecytotoxic pharmaceutical agent and the sterile liquid to form areconstituted cytotoxic formulation; disconnecting the safety connectorfrom the vial adapter (as shown in FIG. 8E); connecting the sterilesyringe to the syringe end of the vial adapter (as shown in FIG. 8F);and withdrawing a predetermined volume of the reconstitutedpharmaceutical agent into the sterile syringe (as shown in FIG. 8G). Themethod may further include disconnecting the sterile syringe from thevial adapter (as shown in FIG. 8H). The method may further includeattaching needle, such as a hypodermic needle or surgical cannula, tothe sterile syringe, the needle being suitable to inject thereconstituted pharmaceutical agent. In some examples, the needle may bea 30-gauge needle, a 29 gauge needle, a 27 gauge needle, or a 25 gaugeneedle. In some embodiments, the method may be performed before, during,or after glaucoma surgery. In some embodiments, the administration by beperformed via injection.

The predetermined dose of the pharmaceutical agent and the predeterminedvolume of the pharmaceutical agent may vary based on the needs of thepatient, as will be appreciated by those having skill in the art. Themethod ensures that an exact dose of the pharmaceutical agent isprepared in a closed system without any exposure to air or to personnelprior to administration to the patient. Those having ordinary skill inthe art will further appreciate that the predetermined dose of thepharmaceutical agent may be accurately measured based on the volume ofsterile diluent provided in the carrier, the mass of the pharmaceuticalagent in the sealed container, and the volume of the reconstitutedpharmaceutical agent withdrawn into the sterile syringe. As anon-limiting example, a carrier may be provided with 1 mL of sterilediluent and a sealed container may be provided with 0.2 mg of thepharmaceutical agent. The reconstituted pharmaceutical agent would thenhave a concentration of 0.2 mg/mL. Therefore, if a 20 μg dose of thepharmaceutical agent is to be administered, a person having ordinaryskill in the art would know to withdraw 0.1 mL of the reconstitutedpharmaceutical agent intended for injection into the sterile syringeprior to administration. Injection may thus be preferred to use of thesterile, absorbent pads because the amount of drug delivered to thetissue may be determined with greater accuracy.

Further provided herein is a method of treatment, the method includingproviding a system described in Section I, optionally in the form of akit described in Section II; connecting the safety connector to thesyringe end of the vial adapter, thereby opening the check valve in thesafety connector and the check valve in the vial adapter; pushing thevial end of the vial adapter onto the sealed container thereby piercinga lid of the sealed container with the spike; injecting the entiresterile diluent from the carrier into the vial via the safety connectorand the vial adapter; inverting the sealed container repeatedly to mixthe cytotoxic pharmaceutical agent and the sterile liquid to form areconstituted cytotoxic formulation; disconnecting the safety connectorfrom the vial adapter; connecting the sterile syringe to the syringe endof the vial adapter; and withdrawing a predetermined volume of thereconstituted pharmaceutical agent into the sterile syringe;disconnecting the sterile syringe from the vial adapter; andadministering the reconstituted pharmaceutical agent to the patient.

In some embodiments, the pharmaceutical agent may be administered viainjection. In embodiments where the pharmaceutical agent is administeredvia injection, a needle may be attached to the sterile syringe afterdisconnecting the sterile syringe from the vial adapter. In someexamples, the needle may be a 30-gauge needle. In some aspects, thepharmaceutical agent may be administered via subconjunctival injection,sub-Tenon injection, intra-Tenon injection or episcleral injection. Theinjection of the pharmaceutical agent may form a bleb. In some examples,the bleb may be shaped and positioned by applying pressure with a wetcotton swab, a blunt tipped instrument, or a Weck-Cel® sponge. Thishelps to control the amount, location and types of tissue exposed to thepharmaceutical agent. In some aspects, the pharmaceutical agent may beadministered via injection into the periocular tissue of the patient. Insome aspects, the periocular tissue may include an episcleral(sub-Tenon's) space.

IV. Pharmaceutical Agent in Reconstitutable Form

A sealed container of the present invention refers to any container thatis suitable for housing a pharmaceutical agent, which includes at leastone pharmaceutically active ingredient (API), and optionally at leastone pharmaceutically acceptable excipient. The pharmaceutical agent isin a form ready to be reconstituted, such as in the form of freeze-dried(lyophilized) powder or an API concentrate.

The pharmaceutical agent may include an antimetabolite agent. In someembodiments, the antimetabolite agent may include mitomycin C (MMC),mercaptopurine, fludarabine, fluorouracil, gemcitabine, cytarabine,pemetrexed, methotrexate, capecitabine, hydroxyurea, cladribine,pralatrexate, thioguanine, nelarabine, floxuridine, decitabine,clofarabine, or other antimetabolite agents known in the art andcombinations thereof. In a preferred embodiment, the antimetaboliteagent is MMC. MMC is commercially available in a lyophilized powderform, which is reconstituted prior to use with normal saline, a balancedsalt solution or sterile water. In an exemplary embodiment, thepharmaceutical agent is Mitosol®.

The amount of the pharmaceutical agent in the container can comprisefrom about 0.01 mg to about 40 mg, from about 0.01 mg to about 0.5 mg,from about 0.5 mg to about 1 mg, from about 1 mg to about 2 mg, fromabout 2 to about 5 mg, from about 5 to about 7 mg, from about 7 to about10 mg, from about 10 mg to about 20 mg, from about 20 mg to about 30 mg,or from about 30 mg to about 40 mg. In one embodiment, thepharmaceutical agent is MMC in an amount of 0.01 mg, 0.2 mg, 0.3 mg, 0.4mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, or40 mg. For example, the container may include 0.2 mg of lyophilizedmitomycin-c powder.

Optionally, pharmaceutically acceptable excipients may be admixed withan API in a pharmaceutically acceptable manner. Non-limiting examples ofpharmaceutically acceptable excipients include chemical enhancers,cryoprotectants, antioxidants, preservatives, solubilizers, adjuvants,osmotic diuretics, carriers, vehicles, coatings, and any combinationsthereof. Optionally, the pharmaceutically acceptable excipients may bepreservative-free. One or more excipients can be selected for topical,parenteral, intraperitoneal, intravascular, intramuscular, subcutaneous,subconjunctival and/or sub-Tenon administration.

A. Cryoprotectants

A cryoprotectant is an excipient that prevents damage to API duringfreezing and drying cycle. Non-limiting examples of cryoprotectantsinclude glycerol, propylene glycol, dimethyl sulfoxide (DMSO).

B. Preservatives

Preservatives are natural or man-made chemicals that may prevent thegrowth or proliferation of microorganisms in medical or food products.They can be called be called antimicrobials, antioxidants, or evenanti-infectives. Sometimes, preservatives may not be desired, due toallergy or other reasons. Thus, “preservative-free” of thepharmaceutical agent is one feature of the instant invention.Non-limiting examples of preservatives include, but are not limited to,ascorbic acid and its salts, ascorbyl palm itate, ascorbyl stearate,anoxomer, N-acetylcysteine, benzyl isothiocyanate, m-aminobenzoic acid,o-aminobenzoic acid, p-aminobenzoic acid (PABA), butylatedhydroxyanisole (BHA), butylated hydroxytoluene (BHT), caffeic acid,canthaxantin, alpha-carotene, beta-carotene, beta-caraotene,beta-apo-carotenoic acid, carnosol, carvacrol, catechins, cetyl gallate,chlorogenic acid, citric acid and its salts, clove extract, coffee beanextract, p-coumaric acid, 3,4-dihydroxybenzoic acid,N,N′-diphenyl-p-phenylenediamine (DPPD), dilauryl thiodipropionate,distearyl thiodipropionate, 2,6-di-tert-butylphenol, dodecyl gallate,edetic acid, ellagic acid, erythorbic acid, sodium erythorbate,esculetin, esculin, 6-ethoxy-1,2-dihydro-2,2,4-trimethylquinoline, ethylgallate, ethyl maltol, ethylenediaminetetraacetic acid (EDTA),eucalyptus extract, eugenol, ferulic acid, flavonoids (e.g., catechin,epicatechin, epicatechin gallate, epigallocatechin (EGC),epigallocatechin gallate (EGCG), polyphenol epigallocatechin-3-gallate),flavones (e.g., apigenin, chrysin, luteolin), flavonols (e.g.,datiscetin, myricetin, daemfero), flavanones, fraxetin, fumaric acid,gallic acid, gentian extract, gluconic acid, glycine, gum guaiacum,hesperetin, alpha-hydroxybenzyl phosphinic acid, hydroxycinammic acid,hydroxyglutaric acid, hydroquinone, N-hydroxysuccinic acid,hydroxytryrosol, hydroxyurea, rice bran extract, lactic acid and itssalts, lecithin, lecithin citrate; R-alpha-lipoic acid, lutein,lycopene, malic acid, maltol, 5-methoxy tryptamine, methyl gallate,monoglyceride citrate; monoisopropyl citrate; morin,beta-naphthoflavone, nordihydroguaiaretic acid (NDGA), octyl gallate,oxalic acid, palmityl citrate, phenothiazine, phosphatidylcholine,phosphoric acid, phosphates, phytic acid, phytylubichromel, pimentoextract, propyl gallate, polyphosphates, quercetin, trans-resveratrol,rosemary extract, rosmarinic acid, sage extract, sesamol, silymarin,sinapic acid, succinic acid, stearyl citrate, syringic acid, tartaricacid, thymol, tocopherols (i.e., alpha-, beta-, gamma- anddelta-tocopherol), tocotrienols (i.e., alpha-, beta-, gamma- anddelta-tocotrienols), tyrosol, vanilic acid,2,6-di-tert-butyl-4-hydroxymethylphenol (i.e., lonox 100),2,4-(tris-3′,5′-bi-tert-butyl-4′-hydroxybenzyl)-mesitylene (i.e., lonox330), 2,4,5-trihydroxybutyrophenone, ubiquinone, tertiary butylhydroquinone (TBHQ), thiodipropionic acid, trihydroxy butyrophenone,tryptamine, tyramine, uric acid, vitamin K and derivatives, vitamin Q10,wheat germ oil, zeaxanthin, or combinations thereof.

C. Dispersants

Dispersants may include but are not limited to starch, alginic acid,polyvinylpyrrolidones, guar gum, kaolin, bentonite, purified woodcellulose, sodium starch glycolate, isoamorphous silicate, andmicrocrystalline cellulose as high hydrophilic-lipophilic balance (HLB)emulsifier surfactants.

D. pH modifiers

Non-limiting examples of pH modifiers include hydrochloric acid, citricacid, acetic acid, tartaric acid, malic acid, fumaric acid, lactic acid,phosphoric acid, sorbic acid, benzoic acid, sodium carbonate and sodiumbicarbonate.

E. Antimicrobial agents

An antimicrobial agent may be included as an excipient to minimize thedegradation of the compound according to this disclosure by microbialagents, including but not limited to bacteria and fungi. Non-limitingexamples of antimicrobials include parabens, chlorobutanol, phenol,calcium propionate, sodium nitrate, sodium nitrite, Na₂EDTA, andsulfites including but not limited to sulfur dioxide, sodium bisulfite,and potassium hydrogen sulfite.

F. Osmotic Diuretics

An osmotic diuretic is a type of diuretic that inhibits reabsorption ofwater and sodium (Na). It is a pharmacologically inert substance that,when used properly, allows appropriate exposure of API to the tissue, sothat the maximum bioavailability can be achieved. Examples of osmoticdiuretic include mannitol and isosorbide. The pharmaceutical agent ofthe current invention may comprise excipients of osmotic diuretics, suchas mannitol or isosorbide.

Exemplary Embodiments

Embodiment 1: A sterile, closed system for preparing cytotoxicformulation to body tissue comprising:

a sealed container of a single dose of a cytotoxic pharmaceutical agentin a reconstitutable form;

a carrier containing a sterile liquid;

a safety connector comprising a check valve, the safety connectorpermanently connected to the carrier; and

a vial adapter comprising a check valve, a vial end, and a syringe end,the vial adapter operable to removably connect to the sealed containervia a spike at the vial end and connect to the safety connector at thesyringe end,

wherein:

the check valve in the safety connector and the check valve in the vialadapter each open only when the safety connector is properly connectedto the vial adapter,

the carrier is operable to deliver the sterile liquid to the sealedcontainer via the safety connector and the vial adapter and withdraw acytotoxic formulation comprising a reconstituted mixture of thecytotoxic pharmaceutical agent and sterile liquid, and

the connections between the carrier, safety connector, and vial adapterremain sterile.

Embodiment 2: The system of embodiment 1, wherein the cytotoxicpharmaceutical agent comprises at least one antimetabolite agent.

Embodiment 3: The system of embodiment 2, wherein the at least oneantimetabolite agent is mitomycin-C.

Embodiment 4: The system of embodiment 1, wherein the cytotoxicpharmaceutical agent in a reconstitutable form comprises a lyophilizedpowder.

Embodiment 5: The system of embodiment 1, wherein the sterile liquidcomprises sterile water.

Embodiment 6: The system of embodiment 1, further comprising a traycomprising:

a compartment with at least one sterile, absorbent pad loosely containedtherein;

and a first cylindrical connector having a first passage that extendsbetween the tray compartment and an exterior of the tray that iscommunicable with the carrier and safety connector for receiving thecytotoxic formulation,

wherein the tray is removably connectable to the safety connector viathe first cylindrical connector, and

wherein the pad is removable from the tray compartment for transientapplication of the cytotoxic formulation to the body tissue.

Embodiment 7: The system of embodiment 1, wherein the at least onesterile absorbent pad comprises an array of pre-cut absorbent pads orsponges with sizes of from 3 to 6 mm, wherein the array comprises atleast one rectangle and at least one half-moon and at least one wedge.

Embodiment 8: The system of embodiment 1, wherein the tray has a coverthat is movable between opened and closed positions for providing accessto the compartment and the pad in the compartment.

Embodiment 9: The system of embodiment 1, further comprising a secondsterile syringe, wherein the tray further comprises a second passage andthe tray is removably connectable with the second sterile syringethrough the second passage.

Embodiment 10: The system of embodiment 9, wherein the second sterilesyringe is operable to aspirate air and/or liquid from the compartmentby a suction force.

Embodiment 11: A kit for sterile preparation of a cytotoxic formulationcomprising:

a sealed container of a single dose of a cytotoxic pharmaceutical agentin a reconstitutable form;

a carrier containing a sterile liquid;

a safety connector comprising a check valve, the safety connectorpermanently connected to the carrier;

a vial adapter comprising a check valve, a vial end, and a syringe end,the vial adapter operable to removably connect to the sealed containervia a spike at the vial end and connect to the safety connector at thesyringe end; and

a sterile packaging container, the sterile packing container comprisingan internal volume that is sealed, the internal volume housing thesealed container, the carrier connected to the safety connector, and thevial adapter in a sterile environment,

wherein:

the check valve in the safety connector and the check valve in the vialadapter each open when the safety connector is properly connected to thevial adapter,

the carrier is operable to deliver the sterile liquid to the sealedcontainer via the safety connector and the vial adapter and withdraw acytotoxic formulation comprising a reconstituted mixture of thecytotoxic pharmaceutical agent and sterile liquid, and

the connections between the carrier, safety connector, and vial adapterremain sterile.

Embodiment 12: The kit of embodiment 11, further comprising aninstruction slip for user direction.

Embodiment 13: The kit of embodiment 11, further comprising a wastecontainer.

Embodiment 14: The kit of embodiment 11, further comprising anon-sterile outer packaging container.

Embodiment 15: The kit of embodiment 11, wherein the cytotoxicpharmaceutical agent comprises at least one antimetabolite agent.

Embodiment 16: The kit of embodiment 15, wherein the at least oneantimetabolite agent is mitomycin-C.

Embodiment 17: The kit of embodiment 11, wherein the cytotoxicpharmaceutical agent in a reconstitutable form comprises a lyophilizedpowder.

Embodiment 18. The kit of embodiment 11, wherein the sterile liquidcomprises sterile water.

Embodiment 19. The kit of embodiment 11, further comprising a traycomprising:

a compartment with at least one sterile, absorbent pad loosely containedtherein; and

a first passage that extends between the tray compartment and anexterior of the tray that is communicable with the carrier and safetyconnector for receiving the cytotoxic formulation,

wherein the tray is removably connectable with the safety connectorthrough the first passage, and

wherein the pad is removable from the tray compartment for transientapplication of the cytotoxic formulation to the body tissue.

Embodiment 20: The kit of embodiment 11, wherein the at least onesterile absorbent pad comprises an array of pre-cut absorbent pads orsponges with sizes of from 3 to 6 mm, wherein the array comprises atleast one rectangle and at least one half-moon and at least one wedge.

Embodiment 21: The kit of embodiment 11, wherein the tray has a coverthat is movable between opened and closed positions for providing accessto the compartment and the pad in the compartment.

Embodiment 22: The kit of embodiment 11, further comprising a sterilesyringe, wherein the tray further comprises a second cylindricalconnector having a second passage and the tray is removably connectablewith the sterile syringe via the second cylindrical connector.

Embodiment 23. The kit of embodiment 22, wherein the sterile syringe isoperable to aspirate air and/or liquid from the compartment by a suctionforce.

Embodiment 24. A method of preparing a cytotoxic formulation foradministration to a tissue, comprising:

providing a sterile, closed system, comprising:

-   -   a sealed container of a single dose of a cytotoxic        pharmaceutical agent in a reconstitutable form;    -   a carrier containing a sterile liquid;    -   a safety connector comprising a check valve, the safety        connector permanently connected to the carrier; and    -   a vial adapter comprising a check valve, a vial end, and a        syringe end, the vial adapter operable to removably connect to        the sealed container via a spike at the vial end and connect to        the safety connector at the syringe end;

connecting the safety connector to the syringe end of the vial adapter,thereby opening the check valve in the safety connector and the checkvalve in the vial adapter;

pushing the vial end of the vial adapter onto the sealed container,thereby piercing a lid of the sealed container with the spike;

injecting the entire sterile water from the carrier into the vial, viathe safety connector and the vial adapter;

inverting the sealed container repeatedly to mix the cytotoxicpharmaceutical agent and sterile liquid to form a reconstitutedcytotoxic formulation;

withdrawing a volume of the cytotoxic formulation back into the carrier;and

disconnecting the safety connector from the vial adapter, therebyclosing the check valve in the safety connector and closing the checkvalve in the vial adapter, wherein the safety connector remainsconnected to the carrier and the vial adapter remains connected to thesealed container.

Embodiment 25: The method of embodiment 24, wherein the cytotoxicpharmaceutical agent comprises at least one antimetabolite agent.

Embodiment 26: The method of embodiment 25, wherein at least oneantimetabolite agent is mitomycin-C.

Embodiment 27: The method of embodiment 26, wherein the concentration ofthe cytotoxic formulation withdrawn into the carrier is at least 0.1mg/mL mitomycin C.

Embodiment 28: The method of embodiment 24, further comprising:

connecting the safety connector to a first passage of a tray comprisinga compartment with at least one sterile, absorbent pad loosely containedtherein; and

connecting a second sterile syringe to a second passage of the tray.

Embodiment 29: The method of embodiment 28, further comprising:

injecting the volume of the cytotoxic formulation in the carrier intothe compartment of the tray, thereby saturating the at least onesterile, absorbent pad; and

withdrawing any excess cytotoxic formulation and/or air into the secondsterile syringe.

Embodiment 30: A method of administering a cytotoxic formulation to atissue, the method comprising:

preparing the cytotoxic formulation according to claim 29;

removing one or more saturated sterile, absorbent pads from thecompartment of the tray; and

applying the one or more saturated sterile, absorbent pads to thetissue.

Embodiment 31: The method of embodiment 30, further comprising removingthe one or more saturated sterile, absorbent pads from the tissue aftera period of time.

Embodiment 32: The method of embodiment 31, wherein the period of timeis 2 minutes.

Embodiment 33: The method of embodiment 30, wherein the tissue isperiocular tissue.

Embodiment 34: The method of embodiment 33, further comprisingperforming a peritomy after removing one or more saturated sterile,absorbent pads.

Embodiment 35: The method of embodiment 33, wherein the perioculartissue receives at least 0.1 mL of the cytotoxic formulation via the oneor more saturated sterile, absorbent pads.

Embodiment 36: The method of embodiment 33, wherein the perioculartissue comprises an episcleral (sub-Tenon's) space.

Embodiment 37: The method of embodiment 33, wherein the cytotoxicformulation is applied to the periocular tissue prior to, during, orafter an ophthalmic surgical procedure.

Embodiment 38: A method of preparing a cytotoxic formulation foradministration to a tissue, the method comprising:

providing a sterile, closed system, comprising:

a sealed container of a single dose of a cytotoxic pharmaceutical agentin a reconstitutable form;

a carrier containing a sterile liquid;

a safety connector comprising a check valve, the safety connectorpermanently connected to the carrier;

a vial adapter comprising a check valve, a vial end, and a syringe end,the vial adapter operable to removably connect to the sealed containervia a spike at the vial end and connect to the safety connector at thesyringe end; and a sterile syringe operable to connect to the vialadapter;

connecting the safety connector to the syringe end of the vial adapter,thereby opening the check valve in the safety connector and the checkvalve in the vial adapter;

pushing the vial end of the vial adapter onto the sealed container,thereby piercing a lid of the sealed container with the spike;

injecting the entire sterile water from the carrier into the vial, viathe safety connector and the vial adapter;

inverting the sealed container repeatedly to mix the cytotoxicpharmaceutical agent and sterile liquid to form a reconstitutedcytotoxic formulation;

disconnecting the vial adapter from the safety connector;

connecting the sterile syringe to the vial adapter; and

withdrawing a predetermined volume of the reconstituted cytotoxicformulation into the sterile syringe.

Embodiment 39: The method of embodiment 38, wherein the administrationis performed via injection.

Embodiment 40: The method of embodiment 38, wherein the predeterminedvolume is less than or equal to 1 mL.

Embodiment 41: The method of embodiment 40, wherein the predeterminedvolume is 0.1 mL.

Embodiment 42: The method of embodiment 38, wherein the reconstitutedcytotoxic formulation has a concentration of about 0.01 mg/mL to about 1mg/m L.

Embodiment 43: The method of embodiment 42, wherein the reconstitutedcytotoxic formulation has a concentration of 0.2 mg/m L.

Embodiment 44: The method of embodiment 38, wherein the pharmaceuticalagent comprises at least one antimetabolite agent.

Embodiment 45: The method of embodiment 44, wherein at least oneantimetabolite agent is mitomycin-C.

Embodiment 46: The method of embodiment 38, further comprisingdisconnecting the sterile syringe from the vial adapter.

Embodiment 47: The method of embodiment 46, further comprising attachinga needle to the sterile syringe.

Embodiment 48: The method of embodiment 47, further comprising injectingthe reconstituted cytotoxic formulation to the periocular tissue of apatient.

Embodiment 49. A method of treating glaucoma, the method comprising:

providing a sterile, closed system, comprising:

a sealed container of a single dose of a cytotoxic pharmaceutical agentin a reconstitutable form;

a carrier containing a sterile liquid and connected to a safetyconnector, the safety connector comprising a check valve, the safetyconnector permanently connected to the carrier;

a vial adapter comprising a check valve, a vial end, and a syringe end,the vial adapter operable to removably connect to the sealed containervia a spike at the vial end and connect to the safety connector at thesyringe end; and

a sterile syringe operable to connect to the vial adapter;

connecting the safety connector to the syringe end of the vial adapter,thereby opening the check valve in the safety connector and the checkvalve in the vial adapter;

pushing the vial end of the vial adapter onto the sealed container,thereby piercing a lid of the sealed container with the spike;

injecting the entire sterile water from the carrier into the vial, viathe safety connector and the vial adapter;

inverting the sealed container repeatedly to mix the cytotoxicpharmaceutical agent and sterile liquid to form a reconstitutedcytotoxic formulation;

disconnecting the vial adapter from the safety connector;

connecting the sterile syringe to the vial adapter;

withdrawing a predetermined volume of the reconstituted cytotoxicformulation into the sterile syringe;

disconnecting the sterile syringe from the vial adapter;

attaching a needle to the sterile syringe; and

injecting the reconstituted cytotoxic formulation to the perioculartissue of a patient in need thereof.

Embodiment 50: The method of embodiment 49, wherein the predeterminedvolume is less than or equal to 1 mL.

Embodiment 51: The method of embodiment 50, wherein the predeterminedvolume is 0.1 mL.

Embodiment 52: The method of embodiment 49, wherein the reconstitutedcytotoxic formulation has a concentration of about 0.01 mg/mL to about 1mg/mL.

Embodiment 53: The method of embodiment 52, wherein the reconstitutedcytotoxic formulation has a concentration of 0.2 mg/mL.

Embodiment 54: The method of embodiment 49, wherein the pharmaceuticalagent comprises at least one antimetabolite agent.

Embodiment 55: The method of embodiment 54, wherein at least oneantimetabolite agent is mitomycin-C.

Embodiment 56: A method of treating glaucoma, the method comprising:

preparing a reconstituted cytotoxic pharmaceutical formulation in asterile, closed system; and

administering a predetermined volume of the reconstituted cytotoxicpharmaceutical formulation to a patient in need thereof.

Embodiment 57: The method of embodiment 56, wherein the sterile, closedsystem comprises:

a sealed container of a single dose of a cytotoxic pharmaceutical agentin a reconstitutable form;

a carrier containing a sterile liquid and connected to a safetyconnector, the safety connector comprising a check valve, the safetyconnector permanently connected to the carrier;

a vial adapter comprising a check valve, a vial end, and a syringe end,the vial adapter operable to removably connect to the sealed containervia a spike at the vial end and connect to the safety connector at thesyringe end; and

a sterile syringe operable to connect to the vial adapter.

Embodiment 58: The method of embodiment 56, wherein the reconstitutedcytotoxic pharmaceutical formulation comprises an antimetabolite agent.

Embodiment 59: The method of embodiment 56, wherein the predeterminedvolume is less than or equal to 1 mL.

Embodiment 60: The method of embodiment 59, wherein the predeterminedvolume is 0.1 mL.

Embodiment 61: The method of embodiment 56, wherein the reconstitutedcytotoxic formulation has a concentration of about 0.01 mg/mL to about 1mg/m L.

Embodiment 62: The method of embodiment 61, wherein the reconstitutedcytotoxic formulation has a concentration of 0.2 mg/m L.

Embodiment 63: The method of embodiment 56, wherein the pharmaceuticalagent comprises at least one antimetabolite agent.

Embodiment 64: The method of embodiment 63, wherein at least oneantimetabolite agent is mitomycin-C.

Examples

The following examples are included to demonstrate the disclosure. Itshould be appreciated by those of skill in the art that the techniquesdisclosed in the following examples represent techniques discovered bythe inventors to function well in the practice of the disclosure. Thoseof skill in the art should, however, in light of the present disclosure,appreciate that many changes could be made in the disclosure and stillobtain a like or similar result without departing from the spirit andscope of the disclosure, therefore all matter set forth is to beinterpreted as illustrative and not in a limiting sense.

Example 1. Study Design and Methodology

A clinical study was set up to compare the efficacy and safety ofsubtenon injection of mitomycin C (MMC) using the instant injectionsystem and kits, with that of conventional application of MMC-soakedsponges in trabeculectomy. Glaucoma patients were randomized into twogroups; group 1 received a subtenon injection of 0.1 mL of 0.01% MMC bythe second sterile syringe, while group 2 received 0.02% MMC-soakedWeck-Cel® sponges to physically disperse the MMC. The injection wasplaced in the far posterior fornix on a 30-guage needle prior to theconjunctival peritomy for trabeculectomy. Primary outcome measure isintraocular pressure (IOP), and secondary outcome measures areendothelial cell count (ECC) changes and bleb morphology according tothe Indiana Bleb Appearance Grading Scale. Outcome measures werecompared at 1, 3 and 6 months postoperatively. Complete and qualifiedsuccess was defined as IOP within 6-15 mm Hg without and withmedications at month 6, respectively.

Data was to be presented in the form of mean, SD, median and range,frequency and percentage values. Normal distribution of data wasassessed by Kolmogrov-Smirnov test and Q-Q plot. To evaluate differencesbetween the study groups, x2, t-test and Mann-Whitney tests. Wilcoxonsinged-rank test and the linear mixed model were used to assess changeswithin the study groups. The Wilcoxon singed-rank test is followed byBonferroni correction to consider multiple comparisons. To compare thegroups adjusted for baseline values, analysis of covariance and Poissonregression (based on the type of response) were used. All statisticalanalyses were performed using SPSS software (IBM SPSS Statistics forWindows, V.23.0, Released 2014, IBM, Armonk, N.Y., USA.). All tests weretwo-sided and p values less than 0.05 were considered statisticallysignificant.

Meanwhile, to evaluate the operability and ease of use on the instantinjection apparatus and kits, a physician questionnaire was distributedto all participating medical staff right after the use of the instantinjection system and kits. The questionnaire included questions on theease of mixing, the time spent on reconstitution, the time and ease ofwithdrawing reconstituted pharmaceutical to the sterile syringe, and thehandle-ability of the system and kits.

Example 2. Study Results

When compared to cellulose sponge delivery, injecting MMC using theinstant invention leads to a lower IOP, a decreased dependence onglaucoma medications, and a more favorable bleb morphology (low anddiffuse) when compared to trabeculectomies performed with sponges. Thus,the study points to non-inferiority with improved predictability of MMCinjection achieved through the use of the instant apparatus and kits.

In response to the questionnaire, a majority of users gave positivefeedback. The users preferred the quick and easy reconstitution, thelessened risk posed by contact, vapor and aerosol hazards, and therapid, reliable and contained transfer to the sterile syringe.

Example 3: Exemplary Instructions for Use of a Kit of the PresentDisclosure

1. Getting Started. Non-sterile Circulating Nurse: Open outer pack.Affect sterile transfer of all contents to the sterile field. SterileSurgical Technician: Open sterile inner tray.

2. Reconstituting the Pharmaceutical Agent. Remove vial and vial adapterfrom foam pouch. Screw plunger rod to rubber plunger of pre-filledcarrier (FIG. 7A). Press firmly and screw the vial end of the vialadapter into the distal end of the safety connector (FIG. 7B).

NOTE: Do not force plunger. Carrier will not operate if vial adapter andsafety connector are not properly connected. Forcing plunger may resultin syringe leakage and Mitosol® exposure.

Stand vial upright on a sturdy, flat surface and push on the vial liduntil seated and secure (FIG. 7C). Inject the entire contents of sterilewater (1 mL) into the vial (FIG. 7D). Do not force carrier plunger (seenote).

IMPORTANT: INVERT VIAL REPEATEDLY to saturate ALL drug product,including that adhering to the stopper, then shake until completereconstitution of Mitosol®. If product does not dissolve immediately,allow to stand at room temperature until the product has dissolved intosolution.

3. Preparing sponges. Invert the vial and carrier and draw full volumeof medication into syringe (FIG. 7E). Remove all sponges from spongetray. Return to sponge tray only those sponges to be saturated withMitosol®. Unscrew the carrier with safety connector from the vial andvial adapter (FIG. 7F). Note: DO NOT remove safety connector from thecarrier.

Place vial and vial adapter in chemotherapy waste disposal bag and setaside, within sterile field, for additional use. Take sponge containerfrom sterile inner tray. Screw carrier and TB syringe into spongecontainer; the TB syringe to one end, the carrier with reconstitutedMitosol® to the other. Mitosol® must be used within 1 hour ofreconstitution. Inject medication into sponge container, saturatingsponges. Reconstituted Mitosol® should remain undisturbed in spongecontainer for 60 seconds (FIG. 7G). Do not force carrier plunger, seenote at step 2. If any excess fluid remains, withdraw plunger of TBsyringe, drawing excess fluid/air into syringe.

4. Using Mitosol®. With the syringe and carrier connected, the TBsyringe to one end, the carrier to the other, open sponge container,offering contents to surgeon for placement on surgical sight (FIG. 7H).

Apply saturated sponges to surgical site for two minutes. Remove spongesfrom eye and copiously irrigate surgical sight. As used sponges areremoved from surgical site, accept used sponges back into spongecontainer for disposal. Close container lid.

With syringes still connected to sponge container, remove entireassembly from surgical field in chemotherapy waste disposal bag. Disposeof chemotherapy waste bag and its contents as chemotherapy waste.

What is claimed is:
 1. A sterile, closed system for preparing cytotoxicformulation to body tissue comprising: a sterile sealed container of asingle dose of a cytotoxic pharmaceutical agent in a reconstitutableform; a sterile carrier containing a sterile liquid; a sterile safetyconnector comprising a check valve, the safety connector permanentlyconnected to the carrier; and a sterile vial adapter comprising a checkvalve, a vial end, and a syringe end, the vial adapter operable toremovably connect to the sealed container via a spike at the vial endand connect to the safety connector at the syringe end, wherein: thecheck valve in the safety connector and the check valve in the vialadapter each open only when the safety connector is properly connectedto the vial adapter, the carrier is operable to deliver the sterileliquid to the sealed container via the safety connector and the vialadapter and withdraw a cytotoxic formulation comprising a reconstitutedmixture of the cytotoxic pharmaceutical agent and sterile liquid, theconnections between the carrier, safety connector, and vial adapterremain sterile, and the carrier, safety connector, and vial adapterremain sterile.
 2. The system of claim 1, wherein the cytotoxicpharmaceutical agent comprises at least one antimetabolite agent.
 3. Thesystem of claim 2, wherein the at least one antimetabolite agent ismitomycin-C.
 4. The system of claim 2, wherein the antimetabolite agentis in an ophthalmic microdose.
 5. The system of claim 1, wherein thecytotoxic pharmaceutical agent in a reconstitutable form comprises alyophilized powder.
 6. The system of claim 1, wherein the sterile liquidcomprises sterile water.
 7. The system of claim 1, further comprising asecond sterile syringe.
 8. A kit for sterile preparation of a cytotoxicformulation comprising: a sterile sealed container of a single dose of acytotoxic pharmaceutical agent in a reconstitutable form; a sterilecarrier containing a sterile liquid; a sterile safety connectorcomprising a check valve, the safety connector permanently connected tothe carrier; a sterile vial adapter comprising a check valve, a vialend, and a syringe end, the vial adapter operable to removably connectto the sealed container via a spike at the vial end and connect to thesafety connector at the syringe end; and a sterile packaging container,the sterile packing container comprising an internal volume that issealed, the internal volume housing the sealed container, the carrierconnected to the safety connector, and the vial adapter in a sterileenvironment, wherein: the check valve in the safety connector and thecheck valve in the vial adapter each open when the safety connector isproperly connected to the vial adapter, the carrier is operable todeliver the sterile liquid to the sealed container via the safetyconnector and the vial adapter and withdraw a cytotoxic formulationcomprising a reconstituted mixture of the cytotoxic pharmaceutical agentand sterile liquid, and the connections between the carrier, safetyconnector, and vial adapter remain sterile.
 9. The kit of claim 8,further comprising an instruction slip for user direction.
 10. The kitof claim 8, further comprising a waste container.
 11. The kit of claim8, further comprising a non-sterile outer packaging container.
 12. Thekit of claim 8, wherein the cytotoxic pharmaceutical agent comprises atleast one antimetabolite agent.
 13. The kit of claim 12, wherein the atleast one antimetabolite agent is mitomycin-C.
 14. The kit of claim 12,wherein the antimetabolite agent is in an ophthalmic microdose.
 15. Thekit of claim 8, wherein the cytotoxic pharmaceutical agent in areconstitutable form comprises a lyophilized powder.
 16. The kit ofclaim 8, wherein the sterile liquid comprises sterile water.
 17. The kitof claim 8, further comprising a second sterile syringe.